ProCE Banner Activity

Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Slideset

Downloadable slides capturing key information on TROP-2‒targeted antibody‒drug conjugates in NSCLC, including available efficacy and safety data, recommended supportive care strategies, and important ongoing clinical trials.

Released: July 25, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.